Corr Daniel, Raikin Jared, O'Neil Joseph, Raikin Steven
Rothman Orthopaedic Institute, Philadelphia, PA, USA.
Thomas Jefferson University Sidney Kimmel Medical College, Philadelphia, PA, USA.
Foot Ankle Int. 2021 Jul;42(7):833-840. doi: 10.1177/1071100721995427. Epub 2021 Mar 10.
Microfracture is the most common reparative surgery for osteochondral lesions of the talus (OLTs). While shown to be effective in short- to midterm outcomes, the fibrocartilage that microfracture produces is both biomechanically and biologically inferior to that of native hyaline cartilage and is susceptible to possible deterioration over time following repair. With orthobiologics being proposed to augment repair, there exists a clear gap in the study of long-term clinical outcomes of microfracture to determine if this added expense is necessary.
A retrospective review of patients undergoing microfracture of an OLT with a single fellowship-trained orthopedic surgeon from 2007 to 2009 was performed. Patients meeting the inclusion criteria were contacted to complete the Foot and Ankle Ability Measure (FAAM) Activities of Daily Living (ADL) and Sports subscales and visual analog scale (VAS) for pain, as well as surveyed regarding their satisfaction with the outcome of the procedure and their likelihood to recommend the procedure to a friend with the same problem using 5-point Likert scales. Patient demographics were reviewed and included for statistical analysis.
Of 45 respondents, 3 patients required additional surgery on their ankle for the osteochondral defect, yielding a 10-year survival rate of 93.3%. Of surviving cases, 90.4% (38/42) reported being "extremely satisfied" or "satisfied" with the outcome of the procedure. The VAS score at follow-up averaged 14 out of 100 (range, 0-75), while the FAAM-ADL and FAAM-Sports scores averaged 90.29 out of 100 and 82 out of 100, respectively. Thirty-six patients (85.7%) stated that their ankle did not prevent them from participating in the sports of their choice.
The current study represents a minimum 10-year follow-up of patients undergoing isolated arthroscopic microfracture for talar osteochondral defects, with a 93.3% survival rate and 85.7% return to sport. While biological adjuvants may play a role in improving the long-term outcomes of microfracture procedures, larger and longer-term follow-up studies are required for procedures using orthobiologics before their cost can be justified for routine use.
Level IV, retrospective cohort case series study.
微骨折术是距骨骨软骨损伤(OLTs)最常见的修复手术。虽然该手术在短期至中期疗效方面已被证明有效,但微骨折术产生的纤维软骨在生物力学和生物学性能上均不如天然透明软骨,且修复后随着时间推移可能会发生退变。随着生物制剂被提议用于增强修复效果,在微骨折术长期临床疗效的研究方面存在明显空白,以确定增加的费用是否必要。
对2007年至2009年由一位接受过单一专科培训的骨科医生为OLTs患者实施微骨折术的病例进行回顾性研究。联系符合纳入标准的患者,让他们完成足踝功能评定量表(FAAM)中的日常生活活动(ADL)和运动亚量表以及疼痛视觉模拟量表(VAS),并通过5级李克特量表调查他们对手术结果的满意度以及向有相同问题的朋友推荐该手术的可能性。对患者的人口统计学数据进行回顾并纳入统计分析。
45名受访者中,3名患者因骨软骨缺损需要对踝关节进行二次手术,10年生存率为93.3%。在存活病例中,90.4%(38/42)报告对手术结果“极其满意”或“满意”。随访时VAS评分平均为100分中的14分(范围为0 - 75分),而FAAM - ADL和FAAM - 运动评分分别平均为100分中的90.29分和82分。36名患者(85.7%)表示他们的踝关节没有妨碍他们参加自己选择的运动。
本研究对接受距骨骨软骨缺损单纯关节镜下微骨折术的患者进行了至少10年的随访,生存率为93.3%,85.7%的患者恢复运动。虽然生物佐剂可能在改善微骨折手术的长期疗效中发挥作用,但在使用生物制剂的手术成本被证明可用于常规使用之前,需要进行更大规模、更长期的随访研究。
IV级,回顾性队列病例系列研究。